The role of T‐cell immunity in COVID‐19 severity amongst people living with type II diabetes

Tong, Zhen; Grant, Emma J.; Gras, Stéphanie; Wu, Melanie; Smith, Corey; Barrett, Helen L.; Gallo, Linda A.; Short, Kirsty R.

doi:10.1111/febs.16105

Cited by 13 publications

(15 citation statements)

References 141 publications

(201 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, Farnsworth et al reported that patients with T2DM exhibit defects in humoral immunity ( Farnsworth et al, 2018 ). There is evidence to suggest that patients with T2DM exhibit decreased cytokine expression and impaired T-cell responses following viral stimulation ( Richard et al, 2017 ; Tong et al, 2021 ). CD4 and CD8 T-cells have been detected in patients with COVID-19 ( Grifoni et al, 2020 ; Tong et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

“…There is evidence to suggest that patients with T2DM exhibit decreased cytokine expression and impaired T-cell responses following viral stimulation ( Richard et al, 2017 ; Tong et al, 2021 ). CD4 and CD8 T-cells have been detected in patients with COVID-19 ( Grifoni et al, 2020 ; Tong et al, 2021 ). This suggests the importance of T-cell responses in COVID-19, and we speculate that the dysfunction of T-cells and lymphocytes in T2DM may affect the progression of COVID-19 disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of common genes and pathways between type 2 diabetes and COVID-19

Wang,

Li,

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

Background:Numerous studies have reported a high incidence and risk of severe illness due to coronavirus disease 2019 (COVID-19) in patients with type 2 diabetes (T2DM). COVID-19 patients may experience elevated or decreased blood sugar levels and may even develop diabetes. However, the molecular mechanisms linking these two diseases remain unclear. This study aimed to identify the common genes and pathways between T2DM and COVID-19.Methods:Two public datasets from the Gene Expression Omnibus (GEO) database (GSE95849 and GSE164805) were analyzed to identify differentially expressed genes (DEGs) in blood between people with and without T2DM and COVID-19. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed on the common DEGs. A protein-protein interaction (PPI) network was constructed to identify common genes, and their diagnostic performance was evaluated by receiver operating characteristic (ROC) curve analysis. Validation was performed on the GSE213313 and GSE15932 datasets. A gene co-expression network was constructed using the GeneMANIA database to explore interactions among core DEGs and their co-expressed genes. Finally, a microRNA (miRNA)-transcription factor (TF)-messenger RNA (mRNA) regulatory network was constructed based on the common feature genes.Results:In the GSE95849 and GSE164805 datasets, 81 upregulated genes and 140 downregulated genes were identified. GO and KEGG enrichment analyses revealed that these DEGs were closely related to the negative regulation of phosphate metabolic processes, the positive regulation of mitotic nuclear division, T-cell co-stimulation, and lymphocyte co-stimulation. Four upregulated common genes (DHX15, USP14, COPS3, TYK2) and one downregulated common feature gene (RIOK2) were identified and showed good diagnostic accuracy for T2DM and COVID-19. The AUC values of DHX15, USP14, COPS3, TYK2, and RIOK2 in T2DM diagnosis were 0.931, 0.917, 0.986, 0.903, and 0.917, respectively. In COVID-19 diagnosis, the AUC values were 0.960, 0.860, 1.0, 0.9, and 0.90, respectively. Validation in the GSE213313 and GSE15932 datasets confirmed these results. The miRNA-TF-mRNA regulatory network showed that TYH2 was targeted by PITX1, PITX2, CRX, NFYA, SREBF1, RELB, NR1L2, and CEBP, whereas miR-124-3p regulates THK2, RIOK2, and USP14.Conclusion:We identified five common feature genes (DHX15, USP14, COPS3, TYK2, and RIOK2) and their co-regulatory pathways between T2DM and COVID-19, which may provide new insights for further molecular mechanism studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Identification of common genes and pathways between type 2 diabetes and COVID-19

Wang,

Li,

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…This impairment of T cell responses in the obese state has also been linked to leptin resistance (144,(251)(252)(253). In COVID-19, lower CD4+ and CD8+ T cell counts were observed in patients with diabetes mellitus upon admission, which correlates with increased disease severity (254). Whether the same defects in T cell responsiveness in obese hosts are observed during SARS-CoV-2 infection, and whether this ultimately derives from the dysregulated inflammatory state, will be important to elucidate.…”

Section: Impact On Adaptive Immune Responsesmentioning

confidence: 99%

“…While metformin has not been used in the clinic to treat severe IAV infection, there have now been clinical studies targeting COVID-19. Metformin reportedly reduces the mortality in women with obesity or Type 2 Diabetes who were admitted to hospital with COVID-19 (254,289).…”

Section: Medical Interventions To Treat Obesity Induced-inflammationmentioning

confidence: 99%

Dysregulated Inflammation During Obesity: Driving Disease Severity in Influenza Virus and SARS-CoV-2 Infections

et al. 2021

Self Cite

View full text Add to dashboard Cite

Acute inflammation is a critical host defense response during viral infection. When dysregulated, inflammation drives immunopathology and tissue damage. Excessive, damaging inflammation is a hallmark of both pandemic influenza A virus (IAV) infections and Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infections. Chronic, low-grade inflammation is also a feature of obesity. In recent years, obesity has been recognized as a growing pandemic with significant mortality and associated costs. Obesity is also an independent risk factor for increased disease severity and death during both IAV and SARS-CoV-2 infection. This review focuses on the effect of obesity on the inflammatory response in the context of viral respiratory infections and how this leads to increased viral pathology. Here, we will review the fundamentals of inflammation, how it is initiated in IAV and SARS-CoV-2 infection and its link to disease severity. We will examine how obesity drives chronic inflammation and trained immunity and how these impact the immune response to IAV and SARS-CoV-2. Finally, we review both medical and non-medical interventions for obesity, how they impact on the inflammatory response and how they could be used to prevent disease severity in obese patients. As projections of global obesity numbers show no sign of slowing down, future pandemic preparedness will require us to consider the metabolic health of the population. Furthermore, if weight-loss alone is insufficient to reduce the risk of increased respiratory virus-related mortality, closer attention must be paid to a patient’s history of health, and new therapeutic options identified.

show abstract

“…The article by Tong et al . [ 7 ] looks at the role of T‐cell immunity in diabetic patients and their response to SARS‐CoV‐2 infection. Through an extensive literature review, the authors provide compelling evidence that a reduced level of T‐cell immunity in patients with type II diabetes links to the poorer prognosis for such patients when exposed to SARS‐CoV‐2.…”

mentioning

confidence: 99%

Spotlight on COVID‐19: eighteen months on

2021

View full text Add to dashboard Cite

In this Editorial, we highlight the contents of The FEBS Journal ’s second Special Issue focussed on COVID‐19. The issue covers a variety of aspects related to COVID‐19, ranging from the most recent improvements in therapies and the significant impact of rapidly developed COVID‐19 vaccines to the emergence of variants of SARS‐CoV‐2, the role of the immune system in the various stages of the disease and the impact of the disease in different organs. We hope that this collection of articles will give readers an informative and critical perspective on recent advances in understanding and treating COVID‐19.

show abstract

The role of T‐cell immunity in COVID‐19 severity amongst people living with type II diabetes

Cited by 13 publications

References 141 publications

Identification of common genes and pathways between type 2 diabetes and COVID-19

Identification of common genes and pathways between type 2 diabetes and COVID-19

Dysregulated Inflammation During Obesity: Driving Disease Severity in Influenza Virus and SARS-CoV-2 Infections

Spotlight on COVID‐19: eighteen months on

Contact Info

Product

Resources

About